Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): NPH-022

            Therapeutic Area: Nephrology Product Name: NPH-022

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Xontogeny, LLC

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Financing May 12, 2021

            Details:

            Funds from the financing to be used to advance Nephraegis' lead compound through critical preclinical work. NPH-022 has demonstrated an impressive efficacy and safety profile in rodent models of renal injury, supporting its potential as a breakthrough candidate.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): TXR-1208

            Therapeutic Area: Nephrology Product Name: TXR-1208

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 04, 2021

            Details:

            TXR-1208 and TXR-1210 represent two different novel mechanisms of action (MOA). The overall timing to complete predictions, select hits and begin in vivo testing was a total of four weeks, significantly faster than traditional drug discovery processes.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Amniotic fluid derived stem cells

            Therapeutic Area: Nephrology Product Name: ImmCelz

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 27, 2021

            Details:

            Creative Medical Technology has filed a patent application disclosing new data in which the ImmCelz® Regenerative Immunotherapy product reduced/reversed kidney failure in an animal model.